Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: Shed syndecan-1 accumulates in fibrotic regions

Modern Pathology

Volumn 14, Issue 10, 2001, Pages 1052-1058

  Bayer Garner, Ilene B ^a   Sanderson, Ralph D ^a,b   Dhodapkar, Madhav V ^c   Owens, Rebecca B ^a   Wilson, Carla S ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

B B4; CD138; Flow cytometry; Immunohistochemistry; Multiple myeloma; Syndecan 1

Indexed keywords

RETICULIN; SYNDECAN; SYNDECAN 1; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW BIOPSY; CELL DIFFERENTIATION; CLINICAL ARTICLE; FIBROSIS; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MULTIPLE MYELOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BIOPSY; BONE MARROW; FIBROSIS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; PROTEOGLYCANS; SYNDECAN-1; SYNDECANS;

EID: 0034780729     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880435     Document Type: Article

References (32)

1. Expression of syndecan-1 regulates human myeloma plasma cell adhesion to type I collagen
2. Expression of syndecan-1 inhibits cell invasion into type-I collagen
3. Heparan sulfate-mediated cell aggregation. Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells
4. Syndecan-1 is a multifunctional regulator of myeloma pathobiology; control of tumor survival, growth, and bone cell differentiation
5. The Mil5 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffinembedded bone marrow biopsy specimens
6. A plasmacyte selective monoclonal antibody (B-B4) recognizes syndecan-1
7. CD138/syndecan-1: A useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies
8. Expression of CD28 and CD40 in human myeloma cells: A comparative study with normal plasma cells
9. Detection of myeloma cells in the peripheral blood by flow cytometry
10. Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen
11. Circulating plasma cells in multiple myeloma: Characterization and correlation with disease stage
12. Elevated levels of shed syndecan-1 correlate with tumor mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma
13. High levels of soluble syndecan-1 in myeloma-derived bone marrow: Modulation of hepatocyte growth factor activity
14. Serum syndecan-1: A new independent prognostic marker in multiple myeloma
15. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells
16. Bone marrow histology in myeloma: Its importance in diagnosis, prognosis, classification, and staging
17. Quantitation of bone marrow reticulin-a normal range
18. Identification and location on syndecan-1 core protein of the epitopes of B-B2 and B-B4 monoclonal antibodies
19. Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissue. A light and electron microscopic study
20. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes
21. Cytoplasmic immunoglobulin content in multiple myeloma
22. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma
23. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression
24. CD138 cluster report
25. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders
26. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation
27. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma
28. The ins and outs of fibroblast growth factors
29. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2
30. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
31. Correlation of bone marrow (BM) microvessel density (MVD) to histology in multiple myeloma (MM)
32. Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density (MVD) in bone marrow biopsies